Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
about
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesNadir CA-125 level as prognosis indicator of high-grade serous ovarian cancer.VEGF pathway polymorphisms as prognostic and pharmacogenetic factors in cancer: a 2013 update.
P2860
Bevacizumab combination therapy: for the first-line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Bevacizumab combination therap ...... or primary peritoneal cancer.
@en
type
label
Bevacizumab combination therap ...... or primary peritoneal cancer.
@en
prefLabel
Bevacizumab combination therap ...... or primary peritoneal cancer.
@en
P2860
P1433
P1476
Bevacizumab combination therap ...... or primary peritoneal cancer.
@en
P2093
Sohita Dhillon
P2860
P304
P356
10.2165/11208940-000000000-00000
P577
2012-05-01T00:00:00Z
P6179
1031502051